



***Inborn errors of metabolism presenting with
kidney stones: clinical aspects***


Francesco Emma

***Division of Nephrology and Dialysis
Bambino Gesù Children's Hospital, IRCCS
Rome, Italy***





Bambino Gesù
OSPEDALE PEDIATRICO

Pediatric renal stones in the western hemisphere




(*) ~65% major component and ~35% principal component

Cross-sectional / prospective data from the Gubbio study




UNa vs Uca

CHILDREN



ADULTS



Hereditary diseases causing calcium-based nephrolithiasis and/or nephrocalcinosis




Figure 3 | Claudins are transmembrane proteins and important components of the tight junctions where they are connected with ZO-1 protein and actin of the cytoskeleton to regulate the paracellular permeability to water and ions and preserve cell polarity. Claudin 16 (CLDN16) is detected in cells of the ascending limb. Its variants may change tight junction permeability and paracellular reabsorption of divalent cations driven by the electric gradient maintained by potassium-channel (ROMK) and sodium-chloride cotransport (NCCT). The calcium-sensing receptor (CASR) inhibits the expression of claudin 16 in tight junctions and the activity of NCCT, thus decreasing the paracellular reabsorption of calcium and magnesium. Claudin 14 is located in cells of the distal convoluted tubule and its role is as yet unclear.




Figure 1 | When the concentration of calcium increases in the tubular fluid, two counterbalancing mechanisms are activated by the calcium-sensing receptor (CASR) in the distal tubule. Here, CASR stimulates proton excretion by H-pump in intercalated cells and decreases water reabsorption by the reduction of aquaporin 2 (AQP2) expression on the apical membrane. As a consequence, urine dilution and acidification protect against calcium-phosphate salt precipitation within the tubular lumen. It is noteworthy that CASR is not a regulator of urine pH or osmolality, but may have a local effect on tubular handling of protons and water. ADP, adenosine diphosphate; ATP, adenosine triphosphate.

Hereditary diseases causing calcium-based nephrolithiasis and/or nephrocalcinosis

Dent

Claudin mutations

RTA

Hyperphosphaturia

Bartter

Gene	Locus/ inheritance mode	Protein	Cellular defect	Tubular defect	Disorder	Ref.
<i>CLCN5</i>	Xp11.22 X-linked recessive	Chloride channel 5 on the endosome membrane	Impaired acidification of the endosome fluid in proximal tubular cells.	Multiple reabsorption defects in the proximal tubule. Stones, nephrocalcinosis and possible end-stage renal failure.	Dent's syndrome	Cho <i>et al.</i> ⁶ and Scheinman <i>et al.</i> ⁷
<i>OCRL1</i>	Xq26.1 X-linked recessive	Phosphatidylinositol 4,5-bisphosphate 5-phosphatase	Accumulation of phosphatidylinositol 4,5- bisphosphate in proximal cells, followed by actin polymerization, and tight and adherens junction defects.	Multiple reabsorption defects in the proximal tubule. Stones, nephrocalcinosis and possible end-stage renal failure. Hydrophthalia, cataract, mental retardation.	Dent's syndrome 2 Lowe syndrome	Cho <i>et al.</i> ⁶
<i>CLDN16</i>	3q27 Autosomal dominant	Claudin 16	Alteration of tight junction ion selectivity in the thick ascending limb of Henle loop.	Urinary loss of magnesium and calcium, nephrocalcinosis, and progressive kidney failure in homozygotes. Heterozygotes may produce kidney stones.	Familial hypomagnesemia with hypercalciuria and nephrocalcinosis	Muller <i>et al.</i> ⁸
<i>CLDN19</i>	1p34.2 Autosomal dominant	Claudin 19	Alteration of tight junction ion selectivity in the thick ascending limb of Henle loop.	Renal wasting of magnesium and calcium, nephrocalcinosis and progressive kidney failure in homozygotes. Macular colobomata, myopia, and nystagmus.	Familial hypomagnesemia with hypercalciuria and nephrocalcinosis with ocular impairment	Konrad <i>et al.</i> ⁹
<i>ATP6N1B</i>	7q33-q34 Autosomal recessive	β -Subunit ATP6N1B of the H-pump	Defect of the proton secretion and urine acidification in the α -intercalated cells of the collecting duct.	Hypokalemic hyperchloremic acidosis with nephrocalcinosis and kidney stones.	Distal tubular acidosis	Smith <i>et al.</i> ¹⁰
<i>ATP6B1</i>	2cen-q13 Autosomal recessive	Subunit ATP6B1 of the H-pump	Defect of the proton secretion and urine acidification in the α -intercalated cells of the collecting duct.	Hypokalemic hyperchloremic acidosis with nephrocalcinosis and kidney stones. Neural deafness.	Distal tubular acidosis with progressive neural deafness	Karet <i>et al.</i> ¹¹
<i>SLC4A1</i>	17q21-q22 Autosomal dominant	Anion exchanger	Decreased bicarbonate reabsorption at the basolateral membrane of the α -intercalated cells of the collecting duct.	Hypokalemic hyperchloremic acidosis, nephrocalcinosis and kidney stones. Kidney stones and incomplete tubular acidosis in heterozygotes.	Distal tubular acidosis	Bruce <i>et al.</i> ¹²
<i>SLC34A3</i>	9q34 Autosomal recessive	NPT2c sodium- phosphate cotransporter	Reduced phosphate reabsorption and increased calcitriol synthesis in the proximal tubular cells.	Severe rickets and kidney stones caused by renal loss of phosphate, hypophosphatemia, and hypercalciuria.	Hypophosphatemic rickets with hypercalciuria	Bergwitz <i>et al.</i> ¹³ and Tencza <i>et al.</i> ¹⁴
<i>CASR</i>	3q13.3-q21 Autosomal dominant	Calcium-sensing receptor (activating mutations)	Inhibition of calcium reabsorption in the ascending limb of Henle loop.	Hypercalciuria and hypocalcemia. Hyperphosphatemia and hypophosphaturia. Renal hypopotassemia if very potent effect of the mutation.	Autosomal-dominant hypoparathyroidism Bartter syndrome type 5	Pearce <i>et al.</i> ¹⁵
<i>SLC12A1</i>	15q15-q21.1 Autosomal recessive	NKCC2 sodium- potassium-chloride transporter	Decreased sodium, potassium and chloride reabsorption in the ascending limb of Henle loop.	Renal hypokalemia, alkalosis, hypercalciuria, secondary aldosteronism and nephrocalcinosis.	Bartter syndrome type 1	Puricelli <i>et al.</i> ¹⁶
<i>KCNJ1</i>	11q24 Autosomal recessive	ROMK1 potassium channel	Decreased sodium, potassium and chloride reabsorption in the ascending limb of Henle loop.	Renal hypokalemia, alkalosis, hypercalciuria, secondary aldosteronism and nephrocalcinosis.	Bartter syndrome type 2	Puricelli <i>et al.</i> ¹⁶


Gene mutations cause phenotypic alterations at protein, cellular, and body level that are described in the table. All these mutations cause a protein loss-of-function with the exception of *CASR* gene mutations that cause nephrolithiasis in the presence of activating mutations.

Underlying diseases causing renal stones

Structure	Disease
$\text{PO}_4\text{-NH}_3\text{-Mg}$ (struvite)	UTI
Calcium phosphate	Hypercalciuria
Calcium oxalate, dihydrated	
Calcium oxalate, monohydrated	Hyperoxaluria
Cystine	Cystinuria
Uric acid	Purine synthesis disorder
2,8-dihydroxyadenine	APRT deficiency
Xanthine	Xanthinuria

Cystinuria

Historical classification	Type I	Type II	Type III
Aminoaciduria heterozygous	N	↑↑	↑
Plasma cystine after oral load	↑↑	↑↑	N
Chromosome	2	19	19
Gene	<i>SLC3A1</i>	<i>SLC7A9</i>	<i>SLC7A9</i>
Protein	rBAT	B ^{0,+} AT	B ^{0,+} AT
Gene-based classification	Type A	Type B	




Cystinuria




Gender effect

Heterozygous carriers


Renal stone emission rate



Percent of patients with renal stones before 3 years of age




Glyoxylate metabolism in the hepatocyte




Genotype-phenotype correlations

PH1-PH2-PH3



Genotype	0-20 y	20-40 y	40-60 y
PH1	76% (129)	43% (49)	12% (7)
PH2	100% (18)	82% (11)	66% (4)
PH3	96% (12)	96% (8)	96% (4)
NMD	100% (14)	100% (12)	100% (7)

PH1




Age	10	20	30	40	50
Survival free from ESRD (no. at risk)					
Homozygous	90% (8)	90% (8)	90% (8)	78% (7)	22% (2)
Heterozygous	91% (18)	85% (14)	60% (9)	33% (5)	20% (3)
Others	78% (69)	52% (31)	31% (18)	22% (12)	7% (4)


PH1 diagnosis

- **Infantile form** **35%**
- **Recurrent stones with progressive CKD** **20%**
- **Late onset during adulthood** **15%**
- **Pedigree screening** **15%**
- **Diagnosis after recurrence on a kidney transplant** **10%**

Oxalate mass balance





Oxalate mass balance




Oxalate nephropathy

- Conditions that promote renal calcium oxalate crystals precipitation:
 - low tubular flow rate (low GFR)
 - high oxalate concentration in the tubular lumen
 - pre-existing tubular damage


(early hours after renal transplantation are at very high risk of precipitation!!!)
- Once calcium oxalate crystals precipitate, they cause **chronic interstitial inflammation** and **irreversible** damage.




Oxalate mass balance



Oxalate mass balance



PH1 disease progression



Conservative management

- High fluid intake (> 3000 ml/m²/24h)
- Potassium citrate
- Try pyridoxine
 - 5-20 mg/Kg/d
 - G170R and P152L mutations
 - goal: Uox reduction >30%
- Orthophosphate (?)
- Hydrochlorothiazide (?)
- Low oxalate diet has limited benefit
(>90% of plasma oxalate is secondary to the liver overproduction)

Early diagnosis is essential

Two sisters with PH1 (AGT Gly170Arg mutation)


- **Lucia**

diagnosed at 2.5 years with creatinine 1.4 mg/dl
now, aged 13, creatinine 2.7 mg/dl

- **Giulia**

diagnosed at birth
medical treatment started immediately
NGT for 6 months to guarantee large fluid intake
now, age 8, creatinine 0.47 mg/dl

Compliance is essential



Primary hyperoxaluria: ESPN/ERA-EDTA Registry




Figure 3. | Unadjusted 3-year survival on RRT in children aged <2 years for PH patients versus non-PH patients (log-rank $P=0.03$). RRT, renal replacement therapy; PH, primary hyperoxaluria.


Oxalate accumulation on dialysis

Oxalate generation : 4-7 mmol/1.73 m²/24h


Removal by conventional dialysis : 1-2 mmol/1.73 m²/24h

Maximizing dialysis


Hemodialyzer



Blood flow



HD + PD



Intensive dialysis can limit oxalate deposition

Migration of a single translucent band



6 months



12 months



16 months




18 months

Even intensive dialysis cannot completely prevent oxalate depositions

Patient age, body weight HD setting, blood flow	Plasma Oxalate, $\mu\text{mol/l}$	Mass Removal, μmol	Generation Rate, $\mu\text{mol/l/h}$	Distribution Volume, L (% of BW)	Tissue Deposition, $\mu\text{mol}/24\text{h}/\text{kg}$	Oxalate clearance, $\text{l}/\text{week}/1.73 \text{ m}^2$
6 months, 5.0 kg daily CVVHD, Qb 40 ml/min	PreHD: 205 PostHD: 31	644	10.0	2.84 (56.8)	5	228
8 months, 6.5 kg daily CVVHD, Qb 50 ml/min	PreHD: 178 PostHD: 41	615	9.14	3.68 (56.7)	19	167
30 months, 12.3 kg HDx6/week, Qb 110 ml/min	PreHD: 102 PostHD: 28	812	4.81	8.28 (67%)	12	185


Primary hyperoxaluria: ESPN/ERA-EDTA Registry




Patients at risk (n)	0	1	2	3	4	5
PH L-KTx	33	30	29	22	19	
PH KTx	7	5	3	3	1	
non-PH	4510	3716	3042	2525	2013	

Prolonged dialysis causes extensive oxalate depositions

Oxalate accumulation after 3 years of PD



Oxalate levels after isolated liver Tx



Pre-emptive liver transplantation

Pre-emptive liver transplantation for PH-I arrests renal function deterioration




Fig. 1. Renal function of patients in both groups at the time of isolated liver transplant and at regular intervals post-transplant.

Transplant strategy

<i>Tx strategy</i>	Simultaneous liver + kidney	Sequential liver–kidney	Isolated kidney	Isolated liver
CKD Stage 3b (30 < GFR < 45)				Expert opinion
CKD Stage 4 (15 < GFR < 29)	++		Gly170Arg? Phe152Ile?	
CKD Stage 5 (GFR < 15)		+++	Gly170Arg? Phe152Ile?	
Infantile form (ESRD < 2 years)		+++		
<i>HD strategy</i>	During and after Tx according to POx and GFR	Standard HD following liver Tx aiming at POx < 20 µmol/L	During and after Tx	Sometimes during Tx

Thank you!

